Current Neuropharmacology最新文献_第9页

Ufmylation: a potential modification for neurological diseases. ufmyation：一种治疗神经系统疾病的潜在方法。

IF 4.8 2区医学

Current Neuropharmacology Pub Date : 2025-01-02 DOI: 10.2174/011570159X340639240905092813

Guanglu Che, Xiao Xiao, Tingyu Li, Jingdong Li, Linbo Gao

{"title":"Ufmylation: a potential modification for neurological diseases.","authors":"Guanglu Che, Xiao Xiao, Tingyu Li, Jingdong Li, Linbo Gao","doi":"10.2174/011570159X340639240905092813","DOIUrl":"https://doi.org/10.2174/011570159X340639240905092813","url":null,"abstract":"Neurological disorders are the leading health threats worldwide, characterized by impairments in consciousness, cognition, movement, and sensation, and can even lead to death. UFMylation is a novel post-translational modification (PTM) that serves as an important regulatory factor, promoting the complexity of protein structures and enhancing the diversity and specificity of functions. In UFMylation, ubiquitin-fold modifier 1 (UFM1) is covalently transferred to the primary amine of a lysine residue on the target protein through the synergistic action of three enzymes: the activating enzyme E1 of UFM1, the coupling enzyme E2 of UFM1, and the ligase E3. UFMylation has been proven to be involved in various cellular processes, such as the maintenance of genome homeostasis, autophagy, signal transduction during antiviral responses, cell death, and differentiation. Additionally, a growing number of evidence suggests that polymorphisms in genes related to the UFMylation system are associated with the risk of epileptic encephalopathy, microcephaly, neurodegenerative diseases, and schizophrenia. Therefore, the concept, enzymatic cascade, and biological functions of UFMylation are carefully summarized, along with its potential role in neurological diseases.","PeriodicalId":10905,"journal":{"name":"Current Neuropharmacology","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142930785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Therapeutic Potential of Dexmedetomidine in Neuropsychiatric Disorders: From the Bench to the Clinic. 右美托咪定在神经精神疾病中的治疗潜力：从实验室到临床。

IF 4.8 2区医学

Current Neuropharmacology Pub Date : 2025-01-02 DOI: 10.2174/011570159X349530241123140415

Xiaojun Hu, Rong Luo, Fan Lei, Xin Li, Yuncheng Luo, Qingran Li, Limei Yi, Xia Zhang, Andrew Polyak, Yuanxiang Tao, Ruotian Jiang

{"title":"Therapeutic Potential of Dexmedetomidine in Neuropsychiatric Disorders: From the Bench to the Clinic.","authors":"Xiaojun Hu, Rong Luo, Fan Lei, Xin Li, Yuncheng Luo, Qingran Li, Limei Yi, Xia Zhang, Andrew Polyak, Yuanxiang Tao, Ruotian Jiang","doi":"10.2174/011570159X349530241123140415","DOIUrl":"https://doi.org/10.2174/011570159X349530241123140415","url":null,"abstract":"Neuropsychiatric disease encompasses a range of conditions resulting from various dysfunctions within the nervous system, manifesting in diverse neurological impairments. These disorders, including depression, schizophrenia, anxiety, and Alzheimer's disease, impose significant economic and psychological burdens on both individuals and society overall. Recent clinical and preclinical studies have highlighted the potential therapy of dexmedetomidine (Dex), a highly selective α2 adrenergic receptor agonist, not only as an effective sedation but also as a neuroprotective agent. Dex exhibits anti-inflammatory and anti-apoptotic effects, as well as contributes to maintaining the integrity of the blood-brain barrier. Clinical observations also supports the application of Dex for the management of neuropsychiatric disorders. Importantly, its side effects in rodents and humans studies are less than those of antipsychotics. In this review, we present a comprehensive overview of the preclinical and clinical evidence supporting the therapeutic efficacy of Dex in neuropsychiatric disorders. We then discussed underlying mechanisms of its effect. Last, we point out future research directions of Dex in the treatment of neuropsychiatric disorders.","PeriodicalId":10905,"journal":{"name":"Current Neuropharmacology","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142930783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Microbiota-Gut-Brain Axis in Age-Related Neurodegenerative Diseases. 老年性神经退行性疾病中的微生物群-肠-脑轴

IF 4.8 2区医学

Current Neuropharmacology Pub Date : 2025-01-01 DOI: 10.2174/1570159X23666241101093436

Tong Nie, Li You, Fang Tang, Yanhui Duan, Eugenie Nepovimova, Kamil Kuca, Qinghua Wu, Wei Wei

{"title":"Microbiota-Gut-Brain Axis in Age-Related Neurodegenerative Diseases.","authors":"Tong Nie, Li You, Fang Tang, Yanhui Duan, Eugenie Nepovimova, Kamil Kuca, Qinghua Wu, Wei Wei","doi":"10.2174/1570159X23666241101093436","DOIUrl":"10.2174/1570159X23666241101093436","url":null,"abstract":"Background: Age-related neurodegenerative diseases (NDs) pose a formidable challenge to healthcare systems worldwide due to their complex pathogenesis, significant morbidity, and mortality. Scope and Approach: This comprehensive review aims to elucidate the central role of the microbiotagut- brain axis (MGBA) in ND pathogenesis. Specifically, it delves into the perturbations within the gut microbiota and its metabolomic landscape, as well as the structural and functional transformations of the gastrointestinal and blood-brain barrier interfaces in ND patients. Additionally, it provides a comprehensive overview of the recent advancements in medicinal and dietary interventions tailored to modulate the MGBA for ND therapy.Conclusion: Accumulating evidence underscores the pivotal role of the gut microbiota in ND pathogenesis through the MGBA. Dysbiosis of the gut microbiota and associated metabolites instigate structural modifications and augmented permeability of both the gastrointestinal barrier and the blood-brain barrier (BBB). These alterations facilitate the transit of microbial molecules from the gut to the brain via neural, endocrine, and immune pathways, potentially contributing to the etiology of NDs. Numerous investigational strategies, encompassing prebiotic and probiotic interventions, pharmaceutical trials, and dietary adaptations, are actively explored to harness the microbiota for ND treatment. This work endeavors to enhance our comprehension of the intricate mechanisms underpinning ND pathogenesis, offering valuable insights for the development of innovative therapeutic modalities targeting these debilitating disorders.","PeriodicalId":10905,"journal":{"name":"Current Neuropharmacology","volume":" ","pages":"524-546"},"PeriodicalIF":4.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142582390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Long-term Efficacy and Safety of Sodium Oxybate in Treating Alcohol Use Disorder: A Systematic Review and Meta-Analysis. 羟丁酸钠治疗酒精使用障碍的长期疗效和安全性：系统回顾与元分析》。

IF 4.8 2区医学

Current Neuropharmacology Pub Date : 2025-01-01 DOI: 10.2174/1570159X22666240902100058

Letizia Biso, Andrea Spini, Francesco Petragnano, Roberto Maggio, Marco Scarselli, Marco Carli

{"title":"Long-term Efficacy and Safety of Sodium Oxybate in Treating Alcohol Use Disorder: A Systematic Review and Meta-Analysis.","authors":"Letizia Biso, Andrea Spini, Francesco Petragnano, Roberto Maggio, Marco Scarselli, Marco Carli","doi":"10.2174/1570159X22666240902100058","DOIUrl":"10.2174/1570159X22666240902100058","url":null,"abstract":"Background: Worldwide, three million deaths each year are reported due to the harmful use of alcohol. To date, only a few drugs have been approved for the treatment of Alcohol Use Disorder (AUD). This systematic review and meta-analysis aim to assess the long-term efficacy and safety of sodium oxybate (SMO) treatment in patients with AUD.Methods: We followed the PRISMA statement guidelines and searched PubMed and ISI Web of Science to retrieve the studies of interest. In total, 13 studies on long-term (>12 weeks) SMO administration in patients with AUD were included in this systematic review, and 7 were included in the metaanalysis.Results: Overall, the abstinence rate after 12 weeks of treatment was similar in the SMO and placebo groups, while it was significantly in favour of SMO compared to Naltrexone (NTX). The completion rate was similar in all three conditions. Mean corpuscular volume (MCV) levels favoured SMO over NTX, while Alcohol Craving Scale (ACS) scores did not favour SMO. The incidence of adverse reactions varied widely between studies.Conclusion: SMO in the chronic treatment of patients with AUD showed no superiority to placebo in our analysis of published RCTs, although many observational studies reported its beneficial effect in the long term. On the contrary, SMO was superior to NTX treatment on abstinence. The rate of study completion was similar in the three groups. Safety was not an issue in any of the studies included. Further studies are needed to better assess SMO efficacy and safety in the long term.","PeriodicalId":10905,"journal":{"name":"Current Neuropharmacology","volume":" ","pages":"579-593"},"PeriodicalIF":4.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142119207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effects of Alcohol on EEG Activity: A Systematic Review Focused on Sex-Related Differences in Youth. 酒精对脑电图活动的影响：以青少年性别差异为重点的系统性综述。

IF 4.8 2区医学

Current Neuropharmacology Pub Date : 2025-01-01 DOI: 10.2174/1570159X23666241106095027

Adrian S Elliott, Roman D Moreno-Fernández, Patricia Sampedro-Piquero

{"title":"Effects of Alcohol on EEG Activity: A Systematic Review Focused on Sex-Related Differences in Youth.","authors":"Adrian S Elliott, Roman D Moreno-Fernández, Patricia Sampedro-Piquero","doi":"10.2174/1570159X23666241106095027","DOIUrl":"10.2174/1570159X23666241106095027","url":null,"abstract":"Background: Most electroencephalographic (EEG) investigations on alcohol have focused on adults, and scarce data is available about the potential of EEG measurements to detect young people at high-risk, as well as, to understand possible sex differences in alcohol impact on the brain.Objective: This systematic review aimed to explore sex-related differences in EEG among young people with alcohol misuse, alcohol use disorder (AUD), and offspring of families with AUD.Methods: A systematic review of the literature was conducted following PRISMA guidelines. Review protocol was registered in Prospero (ID: CRD42024511471). After article selection process and quality assessment, 25 studies were included in our review. The search included participants between 12 and 30 years old with problematic alcohol consumption, as defined by DSM, AUDIT, or specific alcohol misuse questionnaires.Results: It seems that beta was generally higher in young males with AUD, and they usually exhibited greater interhemispheric connectivity (interHC), whereas young females with AUD tended towards enhanced intraHC. P3 appears to be particularly sensitive to alcohol misuse, with males typically exhibiting a lower amplitude than young females. Other event related potentials (ERPs) such as N415, P640, and the error-related negativity (ERN) lacked sufficient methodological support to draw conclusions regarding sex differences, N340 and P540 suggested avenues for expanding research on memory processing, indicating differences in amplitude between males and females.Conclusion: Considering sex variables in clinical research will enhance our understanding of alterations in brain function and structure with the goal of tailoring treatment strategies for AUD.","PeriodicalId":10905,"journal":{"name":"Current Neuropharmacology","volume":" ","pages":"705-727"},"PeriodicalIF":4.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142590456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Metabotropic Glutamate Receptor 5: A Potential Target for Neuropathic Pain Treatment. Metabotropic Glutamate Receptor 5: A Potential Target for Neuropathic Pain Treatment.

IF 4.8 2区医学

Current Neuropharmacology Pub Date : 2025-01-01 DOI: 10.2174/1570159X23666241011163035

Chalton Manengu, Chun-Hao Zhu, Guo-Dong Zhang, Miao-Miao Tian, Xiao-Bing Lan, Li-Jun Tao, Lin Ma, Yue Liu, Jian-Qiang Yu, Ning Liu

引用次数: 0

Oral and Long-acting Injectable Aripiprazole in Severe Mental Illness and Substance Use Disorder Comorbidity: An Updated Systematic Review. 口服和长效注射阿立哌唑治疗严重精神疾病和药物使用障碍合并症：最新系统综述。

IF 4.8 2区医学

Current Neuropharmacology Pub Date : 2025-01-01 DOI: 10.2174/1570159X23666241023115252

Mario Santorelli, Andrea Miuli, Mauro Pettorruso, Francesco Di Carlo, Domenico De Berardis, Stefano L Sensi, Giovanni Martinotti, Massimo Clerici, Massimo di Giannantonio

{"title":"Oral and Long-acting Injectable Aripiprazole in Severe Mental Illness and Substance Use Disorder Comorbidity: An Updated Systematic Review.","authors":"Mario Santorelli, Andrea Miuli, Mauro Pettorruso, Francesco Di Carlo, Domenico De Berardis, Stefano L Sensi, Giovanni Martinotti, Massimo Clerici, Massimo di Giannantonio","doi":"10.2174/1570159X23666241023115252","DOIUrl":"10.2174/1570159X23666241023115252","url":null,"abstract":"Background: Co-occurrence of substance use disorders is frequent in patients with mental health disorders is a condition known as \"dual diagnosis\". The use of substances worsens the prognosis and lowers the quality of life of psychiatric patients. It also increases the risk of hospitalization and suicide rate.Objectives: To assess the effects of aripiprazole therapy on substance use and other psychiatric outcomes in dually diagnosed patients.Methods: We performed a systematic review conducted on 3 databases PUBMED, SCOPUS, and Web of Science, selecting original studies and analyzing the impact of aripiprazole therapy on dually diagnosed patients. Six hundred and fifty-five articles were founded and, after removing duplicates (n = 274) and applying the exclusion criteria, 12 articles were included in our systematic review.Results: 12 studies were included, among which 6 were Randomized Controlled Trials. The Most frequent psychiatric diagnosis were schizoaffective disorders, schizophrenia, and bipolar disorders. Alcohol and cocaine use disorders were the most used substances. Eleven studies showed a clinical improvement after aripiprazole treatment. 8 studies evaluated craving and found a significant reduction after treatment with aripiprazole. No definitive conclusions can be drawn on substance usage and maintenance of abstinence.Conclusion: The present findings suggest aripiprazole may be associated with reducing substance craving and improving depression, psychosis, and schizoaffective disorders in dually diagnosed patients.","PeriodicalId":10905,"journal":{"name":"Current Neuropharmacology","volume":" ","pages":"404-411"},"PeriodicalIF":4.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12105254/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142496675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cortisol Imbalance and Fear Learning in PTSD: Therapeutic Approaches to Control Abnormal Fear Responses. PTSD患者的皮质醇失衡与恐惧学习：控制异常恐惧反应的治疗方法。

IF 4.8 2区医学

Current Neuropharmacology Pub Date : 2025-01-01 DOI: 10.2174/1570159X23666250123142526

Simone Battaglia, Chiara Di Fazio, Sara Borgomaneri, Alessio Avenanti

{"title":"Cortisol Imbalance and Fear Learning in PTSD: Therapeutic Approaches to Control Abnormal Fear Responses.","authors":"Simone Battaglia, Chiara Di Fazio, Sara Borgomaneri, Alessio Avenanti","doi":"10.2174/1570159X23666250123142526","DOIUrl":"10.2174/1570159X23666250123142526","url":null,"abstract":"Post-Traumatic Stress Disorder (PTSD) is mainly characterized by dysregulated fear responses, including hyperarousal and intrusive re-experiencing of traumatic memories. This work delves into the intricate interplay between abnormal fear responses, cortisol dysregulation, and the Hypothalamic-Pituitary-Adrenal (HPA) axis, elucidating their role in the manifestation of PTSD. Given the persistent nature of PTSD symptoms and the limitations of conventional therapies, innovative interventions are urgently needed. One promising avenue of research revolves around the modulation of cortisol through targeting receptors, with dexamethasone emerging as a critical agent capable of reducing cortisol levels, thus potentially aiding in the extinction of fear. In this study, we emphasize the need for innovative interventions in the neuropharmacological treatment of PTSD, focusing on cortisol modulation and its impact on fear regulation mechanisms. The complex interplay between the HPA axis, cortisol modulation, and fear dysregulation not only broadens our comprehension but also reveals promising paths to enhance therapeutic outcomes for individuals struggling with PTSD, underscoring a crucial need for more effective treatment strategies.","PeriodicalId":10905,"journal":{"name":"Current Neuropharmacology","volume":" ","pages":"835-846"},"PeriodicalIF":4.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143032415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Esketamine Treatment Trajectory of Patients with Treatment-Resistant Depression in the Mid and Long-Term Run: Data from REAL-ESK Study Group. 中长期难治性抑郁症患者艾氯胺酮治疗轨迹：REAL-ESK研究组数据

IF 4.8 2区医学

Current Neuropharmacology Pub Date : 2025-01-01 DOI: 10.2174/011570159X337670241029062524

Gianluca Rosso, Giacomo d'Andrea, Stefano Barlati, Marco Di Nicola, Ileana Andriola, Matteo Marcatili, Vassilis Martiadis, Miriam Olivola, Stefania Di Mauro, Gabriele Di Salvo, Pasquale De Fazio, Massimo Clerici, Bernardo Maria Dell'Osso, Antonio Vita, Giorgio Di Lorenzo, Mauro Pettorruso, Giovanni Martinotti, Giuseppe Maina

{"title":"Esketamine Treatment Trajectory of Patients with Treatment-Resistant Depression in the Mid and Long-Term Run: Data from REAL-ESK Study Group.","authors":"Gianluca Rosso, Giacomo d'Andrea, Stefano Barlati, Marco Di Nicola, Ileana Andriola, Matteo Marcatili, Vassilis Martiadis, Miriam Olivola, Stefania Di Mauro, Gabriele Di Salvo, Pasquale De Fazio, Massimo Clerici, Bernardo Maria Dell'Osso, Antonio Vita, Giorgio Di Lorenzo, Mauro Pettorruso, Giovanni Martinotti, Giuseppe Maina","doi":"10.2174/011570159X337670241029062524","DOIUrl":"10.2174/011570159X337670241029062524","url":null,"abstract":"Introduction/objective: Data on long-term treatment with Esketamine Nasal Spray (ESKNS) in real-world patients with treatment resistant depression (TRD) is scarce. The primary aim of the study is to evaluate the effectiveness and tolerability of ESK-NS treatment at 6 and 12-month follow-ups.Methods: This is part of an observational, retrospective, multicentric Italian study (REAL-ESK study). Subjects for the present study underwent psychiatric assessments after 6 and 12 months from the start of ESK-NS treatment. Repeated measures analysis of variance (ANOVA) was used to assess changes in continuous variables, such as scores on psychometric scales from baseline to follow-up time points.Results: Of 63 patients who maintained ESK-NS treatment for at least 6 months, 48 were responders or remitters (76.2%). Among 15 non-responders at 6 months, 4 significantly improved at 12-month follow-up. At least one side effect was reported by 71.8% of subjects with a 6-month follow-up assessment. An overall reduction of side effects was noticed as treatment progressed (42% of patients who continued the treatment reported side effects at 12 months). The most common side effects were sedation (31.7%) and dissociation (28.6%) during ESK-NS sessions. Only 2 patients discontinued ESK-NS for tolerability reasons.Conclusion: The results support the effectiveness and safety of esketamine in the mid and long-term treatment of TRD patients. The late clinical response of a subgroup of patients represents a novel finding. Data needs to be confirmed in larger samples and longer observation periods.","PeriodicalId":10905,"journal":{"name":"Current Neuropharmacology","volume":"23 5","pages":"612-619"},"PeriodicalIF":4.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142982709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A New Augmentation Strategy against Depression Combining SSRIs and the N-terminal Fragment of Galanin (1-15). 结合 SSRIs 和 Galanin (1-15) N 端片段的抗抑郁新策略。

IF 4.8 2区医学

Current Neuropharmacology Pub Date : 2025-01-01 DOI: 10.2174/1570159X23666241003125019

Antonio Flores-Burgess, Carmelo Millon, Noelia Cantero-Garcia, Juan Pedro Pineda-Gomez, Marta Flores-Gomez, Zaida Diaz-Cabiale

引用次数: 0